Celltrion secures EC approval for Remsima SC for five more indications

This article was originally published here

Remsima, which is an infliximab biosimilar, has now been indicated for the treatment of adults having ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Its latest approval

The post Celltrion secures EC approval for Remsima SC for five more indications appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply